Skip to main content
BB Biotech AG logo

BB Biotech AG — Investor Relations & Filings

Ticker · BION ISIN · CH0027659793 LEI · 391200MBZQNPFHIVKO34 SW Financial and insurance activities
Open in API
Filings indexed 267 across all filing types
Latest filing 2025-07-25 Report Publication Anno…
Country CH Switzerland
Listing SW BION

About BB Biotech AG

https://www.bbbiotech.ch/en/bb-biotech

BB Biotech AG is an investment company specializing in the fast-growing biotechnology market. With over 30 years of experience, it is one of the world's largest investors in this sector. The company's investment strategy focuses on a portfolio of publicly listed companies that are developing and commercializing novel drugs. These target companies are selected for their potential to create significant value for the healthcare system by addressing unmet medical needs.

Recent filings

Filing Released Lang Actions
BB Biotech AG publishes its interim report
Report Publication Announcement Classification · 100% confidence The document is an announcement regarding the publication of an interim report. It is short (3632 characters), explicitly states that the company 'publishes its interim report', and provides a link to access the actual report. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the interim report itself.
2025-07-25 English
EQS-News: BB Biotech Q2 2025: outperforms Nasdaq Biotech Index; strong USD returns, currency drag in CHF
Earnings Release Classification · 100% confidence The document is a media release titled 'BB Biotech Q2 2025' which provides a summary of financial performance, portfolio highlights, and strategic updates for the second quarter. While it mentions the 'interim report' is available via a link, the document itself is a press release (Earnings Release) detailing key highlights, performance metrics, and management commentary. It fits the definition of an Earnings Release (ER) as it is the initial announcement of quarterly financial results. Q2 2025
2025-07-25 English
EQS-News: BB Biotech Q2 2025: Outperformance zum Nasdaq Biotech Index – Starke Entwicklung in USD, Wechselkurs belastet Ergebnis in CHF
Earnings Release Classification · 100% confidence The document is a press release from BB Biotech AG regarding their Q2 2025 financial performance. It provides a summary of key highlights, including NAV performance, net loss, portfolio changes, and strategic outlook. While it discusses financial results, it is a summary announcement (17,192 characters, but structured as a media release) that explicitly directs the reader to the full 'Zwischenbericht' (Interim Report) via a provided URL at the end of the text. According to the 'Menu vs Meal' rule, this is a Report Publication Announcement (RPA) rather than the full interim report itself. Q2 2025
2025-07-25 German
EQS-Adhoc: BB Biotech AG publishes its interim report
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) that explicitly states 'BB Biotech AG publishes its interim report' and provides links to access the report externally. According to the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2025-07-25 English
EQS-Adhoc: BB Biotech AG veröffentlicht Zwischenbericht
Report Publication Announcement Classification · 99% confidence The document is a short announcement (approx. 3,300 characters) titled 'BB Biotech AG veröffentlicht Zwischenbericht' (BB Biotech AG publishes interim report). It serves as a notification that the interim report for the period ending June 30, 2025, has been released and provides links to access the full report online. Following the 'Menu vs Meal' rule, this is an announcement of a report rather than the report itself, making it a Report Publication Announcement (RPA).
2025-07-25 German
Half-yearly financial report 2025
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Interim Report as at 30.06.2025' and contains a comprehensive table of contents, consolidated interim financial statements, notes to the financial statements, and a report of the statutory auditors. It provides detailed performance data, a shareholder letter, and portfolio highlights. As it covers a period shorter than a full fiscal year (a half-year report) and includes substantive financial statements and analysis, it is classified as an Interim/Quarterly Report. H1 2025
2025-07-25 English

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.